Above-label doses of octreotide-LAR in patients with metastatic small-intestinal carcinoid tumors.

Abstract

e14579 Background: Octreotide LAR is indicated for treatment of the malignant carcinoid syndrome, and has been studied at doses of 10-30mg intramuscularly every 4 weeks. It has also been proven to delay time to progression of metastatic midgut carcinoid tumors at a dose of 30mg every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhea) or tumor growth while on the maximal labeled dose. We performed a retrospective, longitudinal review of octreotide LAR administration at a tertiary institution to determine the frequency of ‘above-label’ dosing and outcomes. Methods: A retrospective chart-review was performed using a database of patients with metastatic small-bowel carcinoid tumors treated at the Moffitt Cancer Center between the years 2000 and 2010. Data included the maximal dose of octreotide LAR administered, reasons for change in dose or frequency (above the labeled dose of 30mg every 4 weeks), and clinical responses to dose change. Results: 337 patients were considered evaluable, among whom 99 patients (27%) underwent at least one increase in dose or frequency of octreotide-LAR above the standard labeled dose. The most common maximal doses were 40mg every 4 weeks (37 patients), 60mg every 4 weeks (34 patients), and 30mg every 3 weeks (17 patients). The indications for dose increase were worsening carcinoid syndrome (60 patients), radiographic progression (33 patients) and rising urine 5-HIAA (6 patients). Among patients whose doses were increased for refractory carcinoid syndrome, 62% experienced improvement in diarrhea and 56% experienced improvement in flushing. Conclusions: In clinical practice, octreotide LAR is commonly prescribed in doses or schedules above the labled dose and frequency. Patients with refractory carcinoid syndrome appear to experience a clinical benefit from the change. Prospective data is needed to evaluate this strategy.

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

“…ENETS guidelines mention the use of increased dose density or intensity SSA regimens at PD after SD-SSA (5), without clear recommendation because of scarce evidence quality (14)(15)(16)(17)(18).…”

Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study

“…Long-acting SSAs are typically prescribed, with short-acting SSAs used as rescue therapy. Dose escalation of SSAs is possible, based on the severity of symptoms [7,[10][11][12][13][14][15][16][17][18][19]. However, approximately 10-30% of patients may become refractory to treatment and experience recurrent diarrhea and/or flushing episodes whilst on SSAs [20].…”

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome

“…These long-acting therapeutics can slow tumour progression and, importantly, reduce symptoms of CS [19][20][21][22][23]. In patients with particularly severe CS, symptom burden can be further reduced by dose escalation of long-acting SSAs and the addition of short-acting SSAs and anti-diarrheal therapies to the backbone long-acting SSA therapy [8,18,[24][25][26][27][28][29]. However, despite SSA therapy, CS symptoms can persist in approximately 20-40% of patients [24,28,[30][31][32], and over 60% experience sustained debilitating diarrhoea and flushing [30].…”